Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases

his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP). Participants will receive three subtenon injections of autologous platelet-rich plasma (1.5 mL per injection) administered at two-month intervals (M0, M2, M4). The primary objective is to assess functional changes over a 6-month period, with a focus on visual field preservation, evaluated by the Field Preservation Deviation Index (FPDI) and Mean Deviation (MD), as well as best-corrected visual acuity (BCVA, LogMAR). Secondary outcomes include changes in 30-Hz flicker electroretinography (ERG) amplitude, structural retinal parameters on optical coherence tomography (OCT)-including central macular thickness and ellipsoid zone length-and ocular safety outcomes, such as intraocular pressure, local tolerability, and the occurrence of inflammatory or adverse events related to subtenon PRP administration.

NCT Number	NCT07341919
Lead Sponsor	Rubens Camargo Siqueira
Conditions	Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP)
Enrollment	30 participants
Start Date	2025-01-04
Primary Completion	2026-03-04 (estimated)
Study Completion	2027-01-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-01